Baidu
map

Lancet:1–3 个阳性淋巴结患者的乳房切除术后放疗减少复发和乳腺癌死亡率

2014-04-14 MedSci MedSci原创

既往的荟萃分析显示,在合并考虑所有患有淋巴结阳性疾病的女性患者时,乳房切除术后放疗可减少复发和乳腺癌死亡风险。 但是,在仅有一到三个阳性淋巴结的女性中其效果尚不确定。 我们的目的是:评估在这些女性中,乳房切除术和腋窝淋巴结清扫术后放疗的效果。方法在 1964—86 年间,有 22 项试验将乳房切除术和腋窝手术后进行胸壁和局部淋巴结放疗与在同样的手术后无放疗进行了对比。我们对在这些试验中随机分入治疗

既往的荟萃分析显示,在合并考虑所有患有淋巴结阳性疾病的女性患者时,乳房切除术后放疗可减少复发和乳腺癌死亡风险。 但是,在仅有一到三个阳性淋巴结的女性中其效果尚不确定。 我们的目的是:评估在这些女性中,乳房切除术和腋窝淋巴结清扫术后放疗的效果。

方法

在 1964—86 年间,有 22 项试验将乳房切除术和腋窝手术后进行胸壁和局部淋巴结放疗与在同样的手术后无放疗进行了对比。我们对在这些试验中随机分入治疗组的 8135 名女性的个人数据进行了荟萃分析。 针对复发的随访持续了 10 年,针对死亡率的随访持续至 2009 年 1 月 1 日。 根据试验、个别随访年、入组时的年龄和淋巴结的病理状态对分析进行分层。

结果

3786 名女性接受了至少 II 级的腋窝淋巴结清扫术,其阳性淋巴结数分别为零、一到三个、四个及更多。 所有这些女性所参与的试验中,化疗范围包括胸壁、锁骨上或腋窝(或两者皆有)以及内乳淋巴结。 对于 700 名接受了腋窝淋巴结清扫术,且无阳性淋巴结的女性,放疗对局部复发(双侧显著性水平 [2p]>0.1),总复发(率比 [RR], 放疗比无放疗 1.06, 95% CI 0.76—1.48, 2p>0.1)及乳腺癌死亡率 (RR 1.18, 95% CI 0.89—1.55, 2p>0.1) 均无显著效果。 对于 1314 名接受了腋窝淋巴结清扫术,且具有一到三个阳性淋巴结的女性,放疗可减少局部复发 (2p<0.00001)、总复发 (RR 0.68, 95% CI 0.57—0.82, 2p=0.00006) 和乳腺癌死亡率 (RR 0.80, 95% CI 0.67—0.95, 2p=0.01)。 在这 1314 名女性中,有 1133 人所参与的试验中两个实验组均接受了全身治疗(环磷酰胺、甲氨蝶呤、氟尿嘧啶或他莫昔芬),对于她们而言,放疗也可减少局部复发 (2p<0.00001)、总复发 (RR 0.67, 95% CI 0.55—0.82, 2p=0.00009) 和乳腺癌死亡率 (RR 0.78, 95% CI 0.64—0.94, 2p=0.01)。 对于 1772 名接受了腋窝淋巴结清扫术,且具有四个或更多阳性淋巴结的女性,放疗可减少局部复发 (2p<0.00001)、总复发 (RR 0.79, 95% CI 0.69—0.90, 2p=0.0003) 和乳腺癌死亡率 (RR 0.87, 95% CI 0.77—0.99, 2p=0.04)。

结果解读

对于这些试验中具有一到三个阳性淋巴结的女性,乳房切除术和腋窝淋巴结清扫术后放疗可减少复发和乳腺癌死亡率,即使在给予全身治疗时依然如此。今天许多国家中女性的复发风险均较低,对于她们而言绝对效益可能较小,但由于进行了更有效的放疗,其比例增益有可能增大。 

原始出处:

Ebctcg Early Breast Cancer Trialists' Collaborative Group.Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.Lancet. 2014 Mar 19. pii: S0140-6736(14)60488-8. doi: 10.1016/S0140-6736(14)60488-8. [Epub ahead of print]


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2080923, encodeId=11fa2080923e8, content=<a href='/topic/show?id=22666106671' target=_blank style='color:#2F92EE;'>#术后放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61066, encryptionId=22666106671, topicName=术后放疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Thu Feb 19 01:45:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827767, encodeId=9f60182e7676b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 12:45:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876670, encodeId=6ab518e667035, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon May 26 00:45:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292947, encodeId=8bb3129294e88, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Apr 16 06:45:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2080923, encodeId=11fa2080923e8, content=<a href='/topic/show?id=22666106671' target=_blank style='color:#2F92EE;'>#术后放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61066, encryptionId=22666106671, topicName=术后放疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Thu Feb 19 01:45:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827767, encodeId=9f60182e7676b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 12:45:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876670, encodeId=6ab518e667035, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon May 26 00:45:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292947, encodeId=8bb3129294e88, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Apr 16 06:45:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
    2015-03-09 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=2080923, encodeId=11fa2080923e8, content=<a href='/topic/show?id=22666106671' target=_blank style='color:#2F92EE;'>#术后放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61066, encryptionId=22666106671, topicName=术后放疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Thu Feb 19 01:45:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827767, encodeId=9f60182e7676b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 12:45:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876670, encodeId=6ab518e667035, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon May 26 00:45:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292947, encodeId=8bb3129294e88, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Apr 16 06:45:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2080923, encodeId=11fa2080923e8, content=<a href='/topic/show?id=22666106671' target=_blank style='color:#2F92EE;'>#术后放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61066, encryptionId=22666106671, topicName=术后放疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Thu Feb 19 01:45:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827767, encodeId=9f60182e7676b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 09 12:45:00 CST 2015, time=2015-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876670, encodeId=6ab518e667035, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon May 26 00:45:00 CST 2014, time=2014-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292947, encodeId=8bb3129294e88, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Wed Apr 16 06:45:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
    2014-04-16 sodoo

相关资讯

乳腺癌保乳术后近距离放疗乳房切除术风险加倍

    2011年12月6-10日举行的美国圣安东尼奥乳腺癌大会报告的一项研究显示,接受近距离放疗的女性乳腺癌患者失去乳房的风险较接受全乳放疗者加倍。   美国MD安德森癌症中心放射肿瘤学系助理教授Benjamin D. Smith博士及其同事们评估了2000~2007年诊断的130535例>66岁女性乳腺癌患者的资料。患者接受保乳手术继以部分乳腺加速近距离放疗或

ASSO2013:预防性对侧乳房切除术无益生存反增加并发症

美国肿瘤外科学会(ASSO)年度癌症研讨会上公布的一项研究显示,尽管没有证据表明对侧预防性乳房切除术(CPM)对生存有益,但该手术的开展率仍在不断上升。据10所国家综合癌症网络中心(NCCN)的其中一所报道,从1998年至2007年,分别有21%的原位管癌(DCIS)和17%的I-III期乳腺癌患者在单侧乳房切除术后1年内进行了对侧预防性乳房切除术(CPM)。 俄亥俄州立大学综合癌症中心的外科教

Baidu
map
Baidu
map
Baidu
map